Status:

COMPLETED

Panaceo "MED" for IBS (Irritable Bowel Syndrome)

Lead Sponsor:

Scigenia GmbH

Conditions:

Irritable Bowel Syndrome

Microbial Colonization

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Zeolite clinoptilolite is a volcanic mineral from the group of zeolites. The porous structure is associated with a large inner surface. Due to the anionic framework charge, ions (e.g., Pb\^2+) can be ...

Eligibility Criteria

Inclusion

  • Frequency of discomfort or pain in the abdomen in the last 3 months, more than 1 day per week.
  • Start of the discomfort or pain more than 6 months ago.
  • Improvement of the discomfort or pain associated with bowel movements sometimes, often, frequently, always.
  • Association of the discomfort or pain with a frequency change in bowel movements sometimes, often, frequently, always.
  • Association of the discomfort or pain with a change in stool-consistency sometimes, often, frequently, always.

Exclusion

  • Age: younger than 18, older than 80.
  • Diagnosed inflammatory bowel disease (M. Crohn, Colitis Ulcerosa)
  • Diagnosed nutritional idiosyncrasy
  • Cancer treatment in the last 12 weeks
  • Depression in the last 12 weeks
  • Intake of weight loss supporting medication (Lipase inhibitors)
  • Alcohol, nicotine, drug-abuse
  • Status after organ-transplantation, intake of immunosuppressants
  • Acute or chronic neurologic or psychiatric disease
  • Acute or chronic heart disease or kidney disease
  • Acute or chronic liver damage or any other organ damages
  • Transient severe obstipation in the last 4 weeks
  • Transient acute diarrhea in the last 4 weeks (e.g. intestinal infection)
  • Intestinal cancer
  • Intake of Panaceo MED or other Zeolite in the last 4 weeks
  • Type I Diabetes or severe metabolic disease
  • Infection with fever in the last 4 weeks
  • Intake of cortisone or antibiotics in the last 4 weeks
  • Planed journey of more than 14 days in the next 12 weeks (change of nutritional habits)

Key Trial Info

Start Date :

March 9 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2020

Estimated Enrollment :

41 Patients enrolled

Trial Details

Trial ID

NCT03817645

Start Date

March 9 2018

End Date

June 30 2020

Last Update

March 24 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

SCIgenia GmbH

Vienna, Austria, 1090